Stryker Corporation 10-Q Summary: Q1 2005
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2005. Stryker Corporation is a global leader in orthopaedic products and medical device equipment. Operations are segmented into Orthopaedic Implants (reconstructive, trauma, spine, micro implants) and MedSurg Equipment (powered instruments, endoscopy, patient handling). Domestic sales accounted for 64% of revenue, while international sales represented 36%.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 | Change |
|---|---|---|---|
| Net Sales | $1,202.5 million | $1,035.1 million | +16% |
| Gross Profit | $773.4 million | $666.9 million | +16% |
| Gross Margin | 64.3% | 64.4% | -0.1% |
| Operating Income | $246.2 million | $193.2 million | +27% |
| Net Earnings | $173.1 million | $135.9 million | +27% |
| Diluted EPS | $0.42 | $0.33 | +27% |
| Cash from Operations | $32.0 million | $57.9 million | -45% |
| Cash & Equivalents | $244.7 million | $349.4 million (Dec '04) | -30% |
| Long-Term Debt | $0.7 million | $0.7 million | 0% |
Liquidity: Working capital increased to $1,131.4 million. The company holds $244.7 million in cash and has $824.3 million in available borrowing capacity under existing credit facilities.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 13% increase in Orthopaedic Implants and a 24% increase in MedSurg Equipment. Growth was fueled by unit volume (12%), price increases (2%), acquisitions (1%), and favorable currency (1%).
- Segment Performance: Orthopaedic Implants sales rose to $714.4 million (Trauma +20%, Knees +14%). MedSurg Equipment sales rose to $423.0 million (Endoscopy +31%, Powered Instruments +20%).
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales (37.4% vs. 39.7%) due to lower meeting costs and insurance premiums, despite higher sales commissions.
- Tax Rate: The effective income tax rate improved to 29.5% from 30.0% in Q1 2004, attributed to increased manufacturing in lower-tax jurisdictions.
- Cash Flow: Operating cash flow declined significantly ($32.0M vs $57.9M) primarily due to timing of accounts payable payments and higher income tax payments.
Guidance, Outlook, and Risks
- 2005 Outlook: Management expects diluted EPS to approximate $1.75. Net sales growth is projected at 15-16% (14-15% excluding currency), driven by Orthopaedic and MedSurg growth and Physical Therapy Services.
- Acquisitions: Acquired eTrauma.com Corp. for ~$50 million in cash to expand endoscopic and video imaging capabilities. $30.4 million allocated to goodwill.
- Legal Contingencies: The company is cooperating with a Department of Justice investigation regarding billing practices of its subsidiary Physiotherapy Associates and consulting contracts with orthopedic surgeons. No material losses are anticipated beyond current provisions.
- Accounting Changes: Plans to adopt FASB Statement No. 123(R) regarding stock-based compensation effective January 1, 2006. Management does not expect a material impact on earnings trends.
- Foreign Currency: A weakening of foreign currencies reduced the value of international net assets by $48.2 million in Q1 2005, recorded in accumulated other comprehensive gain.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and revenue contribution of the eTrauma.com acquisition.
- Legal Exposure: Monitor developments in the DOJ investigations regarding billing practices and surgeon remuneration agreements.
- Product Launches: Track the performance of new product launches mentioned (Triathlon knee, Gamma3 Hip Fracture System, T2 Nailing System).
- Stock Compensation Impact: Review the impact of the upcoming FASB 123(R) adoption on future reported earnings.
- Currency Sensitivity: Assess the impact of foreign exchange rate fluctuations on future international sales and asset valuations.